Agreement - May 22, 2017
AstraZeneca in agreement with Recordati
AstraZeneca has entered into an agreement with Recordati for the commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination treatments in Europe. Metoprolol succinate is a beta-blocker for the control of hypertension, angina and heart failure. Recordati will pay AstraZeneca $300 million upon completion of the agreement. AstraZeneca will also receive sales-related income through […]